Header image
![](/sites/default/files/styles/page_header_image/public/2023-07/foto_zahlavi_research_1.jpg?itok=p7pBtlZR)
Targeting genotoxic and proteotoxic stress-response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram
Targeting genotoxic and proteotoxic stress-response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram.
The Prostate.
2018,
79(4),
352-362,
ISSN: 0270-4137,
PMID: 30499118,